Syntrix Biosystems, Inc.

Publicly observed

Auburn, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Auburn	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Syntrix Biosystems, Inc.	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	L5Z8K6ZE8LY4	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant14 Sept 2026Publicly observed
NIH SBIR/STTR award: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients
USD 406,500.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Grant1 May 2025Publicly observed
NIH SBIR/STTR award: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
USD 740,293.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Grant1 May 2025Publicly observed
NIH SBIR/STTR award: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
USD 627,270.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Grant7 Jul 2023Publicly observed
NIH SBIR/STTR award: A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
USD 575,793.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Grant7 Jul 2023Publicly observed
NIH SBIR/STTR award: A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
USD 903,852.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.